Semaglutid zur Behandlung der nichtalkoholischen Steatohepatitis

Semaglutide for the treatment of nonalcoholic steatohepatitis

This is a preview of subscription content, access via your institution.

Access options

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

1.
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679–690
CAS Article Google Scholar
2.
Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M (2020) Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1‑3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 46(2):100–109
CAS Article Google Scholar
3.
Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5):1547–1554
CAS Article Google Scholar

Institut für klinische Diabetologie, Deutsches Diabetes-Zentrum an der Heinrich-Heine-Universität, Leibniz-Zentrum für Diabetesforschung, Auf’m Hennekamp 65, 40225, Düsseldorf, Deutschland
Dr. Sabine Kahl

Authors

Dr. Sabine Kahl
View author publications
You can also search for this author in PubMed Google Scholar

Correspondence to Dr. Sabine Kahl.

S. Kahl gibt an, dass kein Interessenkonflikt besteht.

Kahl, S. Semaglutid zur Behandlung der nichtalkoholischen Steatohepatitis. Diabetologe (2021). https://doi.org/10.1007/s11428-021-00733-z